Search Results - "Felix, J M"

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study by Toorop, Myrthe M. A., Rein, Nienke, Nierman, Melchior C., Vermaas, Helga W., Huisman, Menno V., Meer, Felix J. M., Cannegieter, Suzanne C., Lijfering, Willem M.

“…Background Direct oral anticoagulants (DOACs) do not require concentration monitoring. However, whether DOAC concentrations are stable and their variation…”
Get full text

Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case‐cohort by Camilleri, Eleonora, Ghobreyal, Mira, Bos, Mettine H. A., Reitsma, Pieter H., Van Der Meer, Felix J. M., Swen, Jesse J., Cannegieter, Suzanne C., Rein, Nienke

“…Background Major bleeding occurs annually in 1%–3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved…”
Get full text

Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists by Heteren, D. Max, Lijfering, Willem M., Meer, Felix J. M., Reitsma, Pieter H., Swen, Jesse J., Bos, Mettine H. A., Rein, Nienke

Get full text

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence? by Toorop, Myrthe M. A., Chen, Qingui, Kruip, Marieke J. H. A., Meer, Felix J. M., Nierman, Melchior C., Faber, Laura, Goede, Lies, Cannegieter, Suzanne C., Lijfering, Willem M.

“…Background Non‐valvular atrial fibrillation (NVAF) patients are advised to switch from a vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) when…”
Get full text

The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment by Kooiman, Judith, van Hagen, Nadja, Iglesias Del Sol, Antonio, Planken, Erwin V, Lip, Gregory Y H, van der Meer, Felix J M, Cannegieter, Suzanne C, Klok, Frederikus A, Huisman, Menno V

“…The HAS-BLED score enables a risk estimate of major bleeds in patients with atrial fibrillation on vitamin K-antagonists (VKA) treatment, but has not been…”
Get full text

Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism by Boon, Gudula J A M, Rein, Nienke van, Bogaard, Harm Jan, Ende-Verhaar, Yvonne M, Huisman, Menno V, Kroft, Lucia J M, Meer, Felix J M van der, Meijboom, Lilian J, Symersky, Petr, Vonk Noordegraaf, Anton, Klok, Frederikus A

“…The pathophysiology of chronic thromboembolic pulmonary hypertension (CTEPH) is not fully understood. Poor-quality anticoagulation may contribute to a higher…”
Get full text

Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial by Schol‐Gelok, Suzanne, Maat, Moniek P. M., Biedermann, Joseph S., Gelder, Teun, Leebeek, Frank W. G., Lijfering, Willem M., Meer, Felix J. M., Rijken, Dingeman C., Versmissen, Jorie, Kruip, Marieke J. H. A.

“…We conducted a study to assess the effect of rosuvastatin use on fibrinolysis in patients with previous venous thromboembolism (VTE). This was a post hoc…”
Get full text

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns by Toorop, Myrthe M. A., Rein, Nienke, Nierman, Melchior C., Vermaas, Helga W., Huisman, Menno V., Meer, Felix J. M., Cannegieter, Suzanne C., Lijfering, Willem M.

“…Background Since direct oral anticoagulants (DOACs) have been introduced for treatment and prevention of thromboembolic diseases, patients on vitamin K…”
Get full text

Genetic diversity and population structure of three native cattle populations in Mozambique by King, Felix J. M., Banga, Cuthbert B., Visser, Carina

“…In the present work, the population diversity and structure of three populations of native Mozambican cattle were studied, to develop knowledge that is…”
Get full text

Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study by Zielinski, Gilda D., Rein, Nienke, Teichert, Martina, Klok, Frederikus A., Rosendaal, Frits R., Meer, Felix J. M., Huisman, Menno V., Cannegieter, Suzanne C., Lijfering, Willem M.

“…Background Adherence to direct oral anticoagulants (DOACs) in patients with atrial fibrillation in every day practice may be less than in clinical trials. Aims…”
Get full text

Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin‐K antagonists: A randomized controlled trial by Mertens, Bram J., Kwint, Henk‐Frans, Belitser, Svetlana V., Meer, Felix J. M., Marum, Rob J., Bouvy, Marcel L.

“…Background A high number of vitamin K antagonist (VKA) users have a low proportion of time in therapeutic range (TTR) resulting in a high number of bleeding…”
Get full text

Venous malformation with multiple palpable phleboliths by M J, Felix Cordelia, M, Kingsly Paul, Agarwal, Shwetha

“…KCI Citation Count: 0…”
Get full text

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study by Zielinski, Gilda Denise, van Rein, Nienke, Teichert, Martina, Klok, Frederikus A., Rosendaal, Frits R., van der Meer, Felix J.M., Huisman, Menno V., Cannegieter, Suzanne C., Lijfering, Willem M.

“…In contrast to vitamin K antagonists (VKA), direct oral anticoagulants (DOAC's) are not strictly monitored and dose titrated by anticoagulation clinics in the…”
Get full text

Correction: Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism by Boon, Gudula J. A. M, van Rein, Nienke, Bogaard, Harm Jan, Ende-Verhaar, Yvonne M, Huisman, Menno V, Kroft, Lucia J. M, van der Meer, Felix J. M, Meijboom, Lilian J, Symersky, Petr, Noordegraaf, Anton Vonk, Klok, Frederikus A

“…[This corrects the article DOI: 10.1371/journal.pone.0232354.]…”
Get full text

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists by van Rein, Nienke, Lijfering, Willem M, Bos, Mettine H A, Herruer, Martien H, Vermaas, Helga W, van der Meer, Felix J M, Reitsma, Pieter H

“…Risk scores for patients who are at high risk for major bleeding complications during treatment with vitamin K antagonists (VKAs) do not perform that well…”
Get full text

A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon by Verhoef, Talitha I, Ragia, Georgia, de Boer, Anthonius, Barallon, Rita, Kolovou, Genovefa, Kolovou, Vana, Konstantinides, Stavros, Le Cessie, Saskia, Maltezos, Efstratios, van der Meer, Felix J.M, Redekop, William K, Remkes, Mary, Rosendaal, Frits R, van Schie, Rianne M.F, Tavridou, Anna, Tziakas, Dimitrios, Wadelius, Mia, Manolopoulos, Vangelis G, Maitland-van der Zee, Anke H

“…A genotype-guided dosing algorithm was compared with a clinical dosing algorithm in patients starting anticoagulation with acenocoumarol or phenprocoumon…”
Get full text

IMPROVED RRS AND TURBIDITY RETRIEVAL FROM OLI IMAGES IN COMPLEX INLAND WATERS: A CASE STUDY FOR LAGUNA DE BAY by Felix, M J, Perez, G J

“…Spatiotemporal monitoring of water quality parameters such as turbidity in inland waters is desirable to better understand productivity and mitigate the…”
Get full text

Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients by Preijers, Tim, Liesner, Ri, Hazendonk, Hendrika C. A. M., Chowdary, Pratima, Driessens, Mariëtte H. E., Hart, Dan P., Laros‐van Gorkom, Britta A. P., Meer, Felix J. M., Meijer, Karina, Fijnvandraat, Karin, Leebeek, Frank W. G., Mathôt, Ron A. A., Cnossen, Marjon H.

“…Aims Population pharmacokinetic (PK) models are increasingly applied to perform individualized dosing of factor VIII (FVIII) concentrates in haemophilia A…”
Get full text

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants by Toorop, Myrthe M.A., van Rein, Nienke, Nierman, Melchior C., Vermaas, Helga W., Huisman, Menno V., van der Meer, Felix J.M., Cannegieter, Suzanne C., Lijfering, Willem M.

“…Many patients who used vitamin K antagonists (VKAs) for long‐term prevention of thromboembolism are now actively switched to a direct oral anticoagulant…”
Get full text

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data by van Schie, Rianne M.F., Wessels, Judith A.M., le Cessie, Saskia, de Boer, Anthonius, Schalekamp, Tom, van der Meer, Felix J.M., Verhoef, Talitha I., van Meegen, Erik, Rosendaal, Frits R., Maitland-van der Zee, Anke-Hilse

“…Aims Polymorphisms in CYP2C9 and VKORC1 influence patients' phenprocoumon (PHE) and acenocoumarol (ACE) dose requirements. To provide physicians with tools to…”
Get full text